Search the Newsreel

Vivos Therapeutics, Inc. Q2 2026: Revenue $5.15M, EPS $(0.31) — 10-Q Summary

Vivos Therapeutics, Inc. reported its second-quarter 2026 financial results, showing revenue of $5.15 million, a 35% increase year-over-year. Despite the revenue growth, the company's net loss attributable to stockholders widened to $5.48 million, though diluted loss per share narrowed to $(0.31) due to an …

Vivos Therapeutics reports 35% revenue increase in Q2 2026 By Investing.com

Vivos Therapeutics Reports 35% Quarterly Revenue Growth, Rising Patient Demand and Second Quarter 2026 Results

VivoSim Labs (NASDAQ: VIVS) Emerges in Drug Toxicity Market as Revenue Growth Guidance Tops 500% – Plus More In Focus

Armistice Capital discloses 4.99% VVOS position in Vivos Therapeutics (VVOS)

Vivos Therapeutics schedules Q2 2026 results, conference call

Vivos Therapeutics Inc (NASDAQ: VVOS) is set to release its second quarter 2026 financial results after market close on August 14, 2026. Following the release, the company will host a conference call at 5:00 pm ET to discuss the results, provide operational updates, and …

Vivos to discuss collaborations’ anticipated effect on revenue growth and cash burn

Vivos Therapeutics (NASDAQ: VVOS) will release its second quarter 2026 financial results after market close on Friday, August 14, 2026, and will host a conference call at 5:00 p.m. Eastern Time. Management plans to discuss strategic collaborations and their anticipated effect on near-term revenue …

Vivos Therapeutics Inc (VVOS) Earnings Forecast: Future EPS & Revenue Growth Estimates

VivoSim: Fiscal Q1 Earnings Snapshot

VivoSim Labs, Inc. (VIVS) reported a fiscal first-quarter loss of $1.3 million, or 25 cents per share. The San Diego-based development-stage company, which focuses on functional human tissue for research, posted revenue of $18,000 for the period.

VivoSim Labs Ord Shs (VIVS) Earnings Forecast: Future EPS & Revenue Growth Estimates

This article provides an earnings forecast for VivoSim Labs Ord Shs (VIVS), detailing its current stock performance, market capitalization, and P/E ratio. It also lists peer comparisons with other biotechnology and medical research companies, indicating the number of ratings and analysts for each. The …

Form 8K Vivos Therapeutics Inc For: 11 August By Investing.com

This article reports that Vivos Therapeutics Inc filed a Form 8K on August 11. It's a brief financial news item from Investing.com, noting the filing for the company with the stock symbol VVOS.

Vivos Therapeutics Strengthens IP for Sleep Apnea Devices

Vivos Oral Appliance Shows Improvement in Insomnia Severity

A single-site clinical study found that Vivos Therapeutics Inc's Vida oral appliance significantly improved insomnia severity in 100% of its 37 adult participants, reducing Insomnia Severity Index scores by an average of 65%. All patients saw at least one classification level improvement, with many …

Streeterville group discloses 9.25% stake in Vivos Therapeutics (VVOS)

Streeterville Capital LLC, Streeterville Management LLC, and John M. Fife have jointly disclosed a 9.25% beneficial ownership stake in Vivos Therapeutics, Inc. (VVOS), totaling 1,812,031 shares. This filing, a Schedule 13G, indicates they hold sole voting and dispositive power over these shares, based on …

Vivos Therapeutics Expands Greenway Health Partnership to Deploy AI-Enabled Platform Across All Clinical and Revenue Operations

Vivos Therapeutics is expanding its partnership with Greenway Health to implement the AI-by-design Novare platform across its clinical and revenue operations, starting with Sleep Centers of Nevada. This collaboration aims to generate significant annual value through increased patient capacity, improved revenue cycles, and substantial …

Vivos AI rollout could recover an estimated 46,000+ work hours in Nevada

Vivos Therapeutics is expanding its partnership with Greenway Health to deploy the AI-by-design Novare platform across its clinical and revenue operations, starting with Sleep Centers of Nevada (SCN). This initiative is estimated to generate about $9.1 million in annual value for Vivos at SCN, …

Vivos Therapeutics Expands AI Workflow Partnership with Greenway Health, Citing Up to $9.1 Million in Annual Value at Sleep Centers of Nevada

Vivos Therapeutics has partnered with Greenway Health to integrate its AI-powered Novare platform into Vivos' Sleep Centers of Nevada, projecting up to $9.1 million in annual value from increased patient capacity and revenue cycle improvements. This AI implementation is expected to save Vivos $1.8 …

VivoPower PLC Stock Historical Valuations

This article provides historical valuation data for VivoPower PLC (HAM:51J) from GuruFocus.com. It includes key financial metrics such as market capitalization, P/B ratio, and enterprise value, noting that the company is currently operating at a loss. The page also highlights seven severe warning signs …

VivoSim Labs (NASDAQ: VIVS) seeks approval for reverse split, warrant share issuance

VivoSim Labs (NASDAQ: VIVS) is seeking stockholder approval for several key proposals at its virtual 2026 annual meeting on September 30, 2026. These include electing Class III directors, ratifying their auditor, an advisory vote on executive compensation, and crucially, approving a board-discretionary reverse stock …

VIVS PE Ratio & Valuation, Is VIVS Overvalued

The article provides a valuation analysis of VivoSim Labs Inc (VIVS), indicating that the stock is currently in the "Fair zone" based on its forward PS ratio. It details various financial metrics such as Price-to-Book (P/B) ratio, Free Cash Flow (FCF) yield, and compares …

VivoSim Labs, Inc. (VIVS) Stock Price, News, Quote & History

This article provides a comprehensive overview of VivoSim Labs, Inc. (VIVS) stock, including its real-time price, historical data, and key financial metrics. It details the company's profile as a biotechnology firm specializing in 3D human tissue models for drug testing and development. The report …

VivoSim Labs Regains Nasdaq Compliance After $6M Milestone and $4M Financing

VivoSim Labs announced it has regained compliance with Nasdaq's minimum stockholders’ equity rule following a $5.0 million milestone payment from Eli Lilly, the release of $1.0 million from escrow, and a $4.0 million financing completed in July 2026. The company reported approximately $10.1 million …

VIVO Forecast — Price Target — Prediction for 2027

This article provides a forecast and price target for VivoPower PLC (VIVO) stock, based on analyst opinions. It highlights that one analyst has a price target of $10.00, with a max and min estimate of $10.00. The article also includes current stock performance data, …

VivoSim Labs regains Nasdaq compliance after cash infusion

VivoSim Labs (NASDAQ:VIVS) has regained compliance with Nasdaq listing rules after receiving a $5.0 million milestone payment from Eli Lilly, a $1.0 million release from escrow, and completing a $4.0 million financing round. These financial infusions, which occurred in July 2026, increased the company's …

VivoSim regains Nasdaq compliance after $10.1 million cash update

VivoSim Labs (VIVS) has announced that it has regained compliance with Nasdaq Listing Rule 5550(b)(1), which mandates a minimum stockholders’ equity of $2.5 million. This compliance was achieved through several events in July 2026, including a $5.0 million milestone payment from Eli Lilly, a …

VivoSim Provides Financial and Listing Compliance Update

VivoSim Labs, Inc. announced it has regained compliance with Nasdaq Listing Rule 5550(b)(1) requiring a minimum stockholders’ equity of $2.5 million. This compliance was achieved through significant financial events in July 2026, including a $5.0 million milestone payment from Eli Lilly and Company, $1.0 …

VivoSim reports 13.4M shares outstanding after July warrant exercises

VivoSim (VIVS) announced it has regained compliance with Nasdaq Listing Rule 5550(b)(1) after receiving a $5.0 million milestone payment and $1.0 million escrow release from Eli Lilly, along with $3.6 million net proceeds from a financing. The company reported $10.1 million cash on hand …

Price to earnings forward of VivoPower PLC Class A – TRADEGATE:51J

This page from TradingView provides financial information for VivoPower PLC Class A (TRADEGATE:51J), specifically focusing on its forward price-to-earnings ratio. The page indicates that the market was closed with no trades at the time of viewing. It appears to be a financial data portal, …

Vivos Therapeutics Announces Issuance of New US Patent Broadening Protection for Its Vivos CARE Oral Medical Device Technology

Vivos Therapeutics announced the issuance of a new US Patent (No. 12,697,190), broadening protection for its Vivos CARE oral medical device technology. This continuation patent, along with a previously issued patent, strengthens the intellectual property around their devices, which have received unprecedented FDA clearances …

VivoPower Ord Shs (VIVO) Earnings Forecast: Future EPS & Revenue Growth Estimates

VivoSim Labs issues 9,896,718 shares on warrant exercises

VivoSim Labs issued 9,896,718 common shares between July 15 and July 31, 2026, due to the exercise of warrants. This issuance significantly increased the shares outstanding to 13,390,789 as of August 3, 2026, up from 3,194,295 on June 30, 2026. The warrant exercises followed …

Vivos Therapeutics Secures New U.S. Patent Expanding Protection for Vivos CARE Technology

Vivos sleep apnea devices gain broader protection after new patent

Vivos Therapeutics announced that the U.S. Patent and Trademark Office has issued a new patent, No. 12,697,190, which broadens protection for its Vivos CARE oral medical devices for sleep apnea treatment. This new patent is a continuation of a prior patent from 2024, providing …